SECTOR UPDATE

2025. 8. 27

Innovation Team

Keunhee Seo, Ph.D.
Team Leader
keunhee.seo@samsung.com

Suhan Shin
Research Associate
shn.shin@samsung.com

Scan to go to
Research Center report database

Healthcare (OVERWEIGHT)

Uncertainty dissipates, momentum remains

- Eased tariff uncertainty and unrelenting global growth momentum provide relief over the export competitiveness of Korean firms.
- In 2H, sector momentum should be driven by sustained investor interest in obesity/diabetes treatments, increased M&A activity among global pharmaceutical companies, and clinical progress across key pipelines.

WHAT'S THE STORY?

US and EU strike pharmaceutical tariff deal: On Aug 21, the US and EU released a joint statement in which the US confirmed that: 1) the combined tariff rate on EU-made pharmaceuticals will not exceed 15%; and 2) for generics and precursors, only the most-favored nation (MFN) tariff will apply from Sep 1. Korea is expected to receive similar treatment. Tariffs on other goods remain under negotiation, with details pending. The higher likelihood of Korean CDMO firms avoiding a tariff shock eases near-term concerns over export competitiveness. However, in the long term, with the US-led trend towards reshoring accelerating, Korean production hubs alone may no longer be sufficient to maintain demand from global clients.

Pharmaceuticals—earnings recovery to be confirmed: In 2H, recovery of earnings momentum will be a key investment focus for the domestic pharmaceutical sector.

- **Celltrion:** A guidance cut for Zymfentra has reset expectations, but growing North American and European sales and production efficiency gains should support earnings growth.
- **ST Pharm:** The firm's oligonucleotide CMO sales should accelerate as partners' therapeutics advance toward global commercialization.
- **HK inno.N:** The company has resolved its beverage recall issue, reducing cost uncertainty. Its K-CAB is likely to be licensed out in Europe before year-end and is likely to file for FDA approval for US market entry.
- **Hanmi Pharmaceutical.** In the short term, Hanmi Pharmaceutical faces short-term volatility due to a dispute over managerial control, though the impact on enterprise value should be limited. Subsidiary Beijing Hanmi is poised for an earnings recovery in 2H, while Merck is set to announce the highly anticipated Phase II outcome for efinopegdutide in 1H26.

(Continued on the next page)

▶ AT A GLANCE

Celltrion (068270 KS, 172,900)		
Target price	KRW220,000	27.2%
BUY		
ST Pharm (237690 KQ, 94,300)		
Target price	KRW110,000	16.6%
BUY		
HK inno.N (195940 KQ, 48,900)		
Target price	KRW55,000	12.5%
BUY		
HanmiPharmaceutical (128940 KS, 298,000)		
Target price	KRW400,000	34.2%
BUY		

Biotech—momentum intact: The biotech sector remains resilient, supported by: 1) expectations of rate cuts; and 2) heightened M&A activity among global pharmaceutical firms seeking to counter patent expiries. Still, the potential impact of year-end capital gains tax on domestic market dynamics warrants attention.

- **Ligachem Biosciences:** The rising prominence of linker technology, a core element of antibody-drug conjugates (ADC), should drive platform technology out-licensing. Visibility of clinical progress across major pipelines validates both technology progress and commercialization potential.
- **Alteogen:** The US Centers for Medicare and Medicaid Services (CMS) is planning to clarify that simple formulation changes cannot be excluded from drug price negotiations, but the near-term impact on Alteogen's profitability should be limited. Instead, the regulatory approval and launch of Merck's subcutaneous Keytruda should enhance Alteogen's licensing opportunities and royalty-driven growth.
- **ABL Bio:** Results from Sanofi's clinical trial of ABL-301 (Parkinson's treatment) are expected. The scalability of ABL Bio's blood-brain barrier (BBB) shuttle platform merits close attention.
- **D&D Pharmatech:** Results from partner Metsera's Phase II trial of MET-097i (long-acting GLP) are pending. Positive results would strengthen expectations for MET-0970/MET-2240, developed with D&D Pharmatech's oral formulation technology, and enhance longer-term pipeline value.

Compliance notice

- As of 8/26 2025, the covering analyst(s) did not own any shares, or debt instruments convertible into shares, of any company covered in this report.
- As of 8/26 2025, Samsung Securities' holdings of shares and debt instruments convertible into shares of each company covered in this report would not, if such debt instruments were converted, exceed 1% of each company's outstanding shares.
- This report has been prepared without any undue external influence or interference, and accurately reflects the views of the analyst(s) covering the company or companies herein.
- All material presented in this report, unless specifically indicated otherwise, is under copyright to Samsung Securities.
- Neither the material nor its content (including copies) may be altered in any form, or by any means transmitted, copied, or distributed to another party, without prior express written permission from Samsung Securities.
- This memorandum is based upon information available to the public. While we have taken all reasonable care to ensure its reliability, we do not guarantee its accuracy or completeness. This memorandum is not intended to be an offer, or a solicitation of any offer, to buy or sell the securities mentioned herein. Samsung Securities shall not be liable whatsoever for any loss, direct or consequential, arising from the use of this memorandum or its contents. Statements made regarding affiliates of Samsung Securities are also based upon publicly available information and do not necessarily represent the views of management at such affiliates.
- This material has not been distributed to institutional investors or other third parties prior to its publication.

Target price changes in past two years









Rating changes over past two years (adjusted share prices)

Celltrion											
Date	2023/3/6	2024/3/6	2024/4/29	12/31	2025/2/11	5/12	6/19	7/21			
Recommendation	BUY	BUY	BUY	BUY	BUY	BUY	BUY	BUY			
Target price (KRW)	193191	193191	229989	229989	221539	211907	210000	220000			
Gap* (average)	-22.30	-13.75	-24.55	-24.16	-24.51	-27.24	-18.76				
(max or min)**	10.24	-8.95	-16.40	-22.31	-17.70	-22.65	-14.10				
ST Pharm											
Date	2023/7/18	10/11	11/2	2024/4/18	6/13	9/9	2025/4/21				
Recommendation	BUY	BUY	BUY	BUY	BUY	BUY	BUY				
Target price (KRW)	110000	100000	90000	100000	120000	130000	110000				
Gap* (average)	-28.34	-29.89	-22.92	-6.16	-21.35	-32.21					
(max or min)**	-24.82	-24.00	7.00	9.60	-3.83	-10.00					
HK inno.N											
Date	2023/7/10	10/4	10/30	12/22	2024/1/10	4/11	9/23	2025/2/12	4/10	4/24	6/9
Recommendation	BUY	BUY	BUY	BUY	BUY	BUY	BUY	BUY	BUY	HOLD	BUY
Target price (KRW)	45000	50000	53000	57000	60000	58000	64000	62000	50000	50000	55000
Gap* (average)	-20.34	-16.08	-21.65	-22.57	-34.22	-31.86	-35.49	-41.66	-25.89	-17.69	
(max or min)**	-6.44	-13.00	-15.09	-18.42	-26.17	-16.55	-21.09	-39.35	-24.70	-12.70	
HanmiPharm											
Date	2023/5/15	2024/1/3	1/11								
Recommendation	BUY	BUY	BUY								
Target price (KRW)	353207	353207	400000								
Gap* (average)	-16.19	-0.23	-21.89								
(max or min)**	1.36	-1.62	-11.75								

Note: * [(average, maximum, or minimum share price over duration of target price minus target price) / target price] x 100%
** Maximum/minimum share price if new target is higher/lower than market close on the business day prior to target price change

Samsung Securities uses the following investment ratings*

Company

BUY	Expected to increase in value by 15% or more within 12 months and is highly attractive within sector
HOLD	Expected to increase/decrease in value by less than 15% within 12 months
SELL	Expected to decrease in value by 15% or more within 12 months

Industry

OVERWEIGHT	Expected to outperform market by 5% or more within 12 months
NEUTRAL	Expected to outperform/underperform market by less than 5% within 12 months
UNDERWEIGHT	Expected to underperform market by 5% or more within 12 months

* Note: Effective Jul 27, 2023, BUY, HOLD, and SELL criteria are based on expectations of share-price moves of 15% or more within 12 months

Percentage of ratings in 12 months prior to 2025.06.30

BUY(81.8%)·HOLD(18.2%)·SELL(0%)

Global Disclosures & Disclaimers

General

This research report is for information purposes only. It is not and should not be construed as an offer or solicitation of an offer to purchase or sell any securities or other financial instruments or to participate in any trading strategy. This report does not provide individually tailored investment advice. This report does not take into account individual client circumstances, objectives, or needs and is not intended as recommendations of particular securities, financial instruments or strategies to any particular client. The securities and other financial instruments discussed in this report may not be suitable for all investors. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein and investors should seek the advice of a financial adviser.

This report may not be altered, reproduced, distributed, transmitted or published in whole or in part for any purpose. References to "Samsung Securities" are references to any company in the Samsung Securities, Co., Ltd. group of companies.

Samsung Securities and/or other affiliated companies, its and their directors, officers, representatives, or employees may have long or short positions in any of the securities or other financial instruments mentioned in this report or of issuers described herein and may purchase and/or sell, or offer to purchase and/or sell, at any time, such securities or other financial instruments in the open market or otherwise, as either a principal or agent. Any pricing of securities or other financial instrument contained herein is as of the close of market for such day, unless otherwise stated. Opinions and estimates contained herein constitute our judgment as of the date of this report and are subject to change without notice.

The information provided in this report is provided "AS IS". Although the information contained herein has been obtained from sources believed to be reliable, no representation or warranty, either expressed or implied, is provided by Samsung Securities in relation to the accuracy, completeness or reliability of such information or that such information was provided for any particular purpose and Samsung Securities expressly disclaims any warranties of merchantability or fitness for a particular purpose. Furthermore, this report is not intended to be a complete statement or summary of the securities, markets or developments referred to herein.

Samsung Securities does not undertake that investors will obtain any profits, nor will it share with investors any investment profits. Samsung Securities, its affiliates, or any of its and their affiliates, directors, officers, employees or agents disclaim any and all responsibility or liability whatsoever for any loss (direct or consequential) or damage arising out of the use of all or any part of this report or its contents or otherwise arising in connection therewith. Information and opinions contained herein are subject to change without notice. Past performance is not indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of Samsung Securities. Any analysis contained herein is based on numerous assumptions. Different assumptions may result in materially different results. Samsung Securities is under no obligation to update or keep current the information contained herein. Samsung Securities relies on information barriers to control the flow of information contained in one or more areas or groups within Samsung Securities into other areas or groups of Samsung Securities. Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other financial instruments. Samsung Securities makes no representation that any transaction can or could have been effected at those prices and any prices contained herein may not reflect Samsung Securities' internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by Samsung Securities or any other source may yield substantially different results. Additional information is available upon request.

For reports to be distributed to US:

Securities research is prepared, issued and exclusively distributed by Samsung Securities Co., Ltd., an organization licensed with the Financial Supervisory Service of South Korea. This research may be distributed in the United States only to major institutional investors as defined in Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended, and may not be circulated to any other person otherwise. All transactions by U.S. investors involving securities discussed in this report must be effected through Samsung Securities (America) Inc., a broker-dealer registered with the U.S. Securities & Exchange Commission and a member of the Financial Industry Regulatory Authority/SIPC, and not through any non-U.S. affiliate thereof. The analysts listed [on the front of this report] are employees of Samsung Securities Co., Ltd., or a non-U.S. affiliate thereof, and are not registered/qualified as research analysts under applicable U.S. rules and regulations and may not be subject to U.S. restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

For reports to be distributed to UK:

This report is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of section 21 of the Financial Services and Markets Act 2000 of the United Kingdom ("FSMA"). To the extent that this report does constitute such an invitation or inducement, it is directed only at (i) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (as amended) of the United Kingdom (the "Financial Promotion Order"); (ii) persons who fall within Articles 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order; and (iii) any other persons to whom this report can, for the purposes of section 21 of FSMA, otherwise lawfully be made (all such persons together being referred to as "relevant persons").

Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons must not act or rely on this report.

For reports to be distributed to Korea:

This report is for private circulation only, not for sale, and is issued and distributed only to persons permitted under the laws and regulations of Korea.

For reports to be distributed to Singapore:

This report is provided pursuant to the financial advisory licensing exemption under Regulation 27(1)(e) of the Financial Advisers Regulation of Singapore and accordingly may only be provided to persons in Singapore who are "institutional investors" as defined in Section 4A of the Securities and Futures Act, Chapter 289 of Singapore. This report is intended only for the person to whom Samsung Securities has provided this report and such person may not send, forward or transmit in any way this report or any copy of this report to any other person.

Analyst certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of such analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research report. The analyst(s) principally responsible for the preparation of this research report receives compensation based on determination by research management and senior management (not including investment banking), based on the overall revenues, including investment banking revenues of Samsung Securities Co., Ltd. and its related entities and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Copyright © 2010 Samsung Securities Co., Ltd.. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the prior written consent of Samsung Securities America Inc

Samsung Securities

SAMSUNG SECURITIES

Samsung Electronics Bldg., 11, 74-gil,
Seochodae-ro, Seocho-gu, Seoul, Korea 06620
Tel: 02 2020 8000 / www.samsungpop.com

Family Center: 1588 2323

Voice Of Customer: 080 911 0900

For more information,
please call our sales representatives:

LONDON

Samsung Securities Europe Limited
1st Floor, 30 Gresham Street, London EC2V 7PG UK
Tel. 44-207-776-4311
Fax. 44-203-837-9219

NEW YORK

Samsung Securities America Limited
1330 Avenue of the Americas. 10th Floor. New York,
NY 10019
Tel: 1-212-972-2454
Fax: 1-212-972-2704

HONG KONG

Samsung Securities (Asia) Limited
Suite 4511, Two International Finance Center,
8 Finance Street, Central, Hong Kong
Tel: 852-3411-3608
Fax: 852-2114-0290

BEIJING

Samsung Securities Beijing Representative Office
Rm. 910, The Exchange Building No 118 JianGuo Lu, Chao
Yang District, Beijing, China
Tel: 86-10-6522-1855 (extension 7891)
Fax: 86-10-6522-1855 (extension 7889)

TOKYO

Samsung Securities Tokyo Representative Office
#106-8532 19F, Roppongi T-Cube 3-1-1,
Roppongi Minato-ku Tokyo, Japan
Tel: 81-3-6333-2952
Fax: 81-3-6333-2953

Member of
Dow Jones
Sustainability Indices
Powered by the S&P Global CSA